⌕
Altimmune · ALT · Nasdaq
Tenet 54 · Mixed
Compare
$1.56−5.17%At closeTenet 54 · Mixed
$1.56−0.09 (−5.17%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Altimmune (ALT) Stock

Altimmune (ALT) closed at $1.56 on Nov 16, 2026; its Tenet Score is 54 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Previous close
$1.56
Nov 16, 2026
Market cap
$303.6M
share price × the latest quarter's diluted weighted-average share count (vendor)
Dividend yield
0.00%
reinvests all
52-week range
1.58 – 6.44
low → high
Tenet Score
54/100
Mixed · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Altimmune Inc scores 54/100. Mixed. Strongest on value and financial health, growth is the soft spot versus 409 Healthcare peers.

Tenet Score · vs sector

n=409
54/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
97
Quality
35
Health
86
Growth
1

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueA+QualityDHealthBGrowthFMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
0.7×
cap ÷ Sep 30, 2026 book value, Nov 13, 2026 close
P/S
7,807.3×
price to fiscal 2025 sales
ROE
−33%
TTM through Sep 30, 2026
Operating margin
−230461.0%
fiscal 2025, before interest and tax
Net margin
—
Not reported in the company's filings for this period.
Current ratio
23.93
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 4y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agon…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 45 US ETFs · top wrappers by weightSee all ETFs holding ALT →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Altimmune in?

Altimmune is in the Healthcare sector and the Drugs industry.

What is Altimmune's Tenet Score?

Altimmune's Tenet Score is 54 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.